Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Environmental impact of pharmaceuticals and personal care products wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Neuropharmacology wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Lithium (medication) wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Psychopharmacology wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Atypical antipsychotic wikipedia , lookup
National Institute for Health and Care Excellence wikipedia , lookup
Drugs → brain structures AP MST Bipolar disorder NICE Diagnosis Full history of the patient (family, any episode, symptoms between the episodes) Symptoms profile, triggers to previous episodes, social and personal functioning, comorbidities, physical health, current psychosocial stressors Interview a family member NICE BE CAREFUL If (Psychotic symptoms, ↑ suicidal ideation, ↑ drug misuse) → late BD and not SKZ (minorities) If alcohol | drug → wait 7 days before diagnosis Late onset (>40yrs) → hypothyroidism, stroke, neurological disorders (dementia) NICE Before a rapid cycling BD is diagnosed consider: Erratic compliance hypothyroidism, AD, suboptimal medication regimes Lithium withdrawal NICE Consider a diagnosis of BD before Axis II if there are mood swings During treatment consider compliance before considering a personality disorder NICE Treatment (1/3) Inform the patient Contraception and risk of pregnancy See patients once / (1|2) week (for 3 months) NICE Treatment (2/3) Acute mania (and mixed→ AP, valproate, lithium, BDZ AP (olanz, risp, quet)→ severe manic symptoms | marked behavioral disturbances Valproate or lithium → previous response, good compliance, augmentation of AP Lithium → not severe symptoms NOT RECOMMENDED: CBZ, Gabapent, Lamo NICE Treatment (3/3) Acute depression Add AP (quetiapine) to AD (SSRI better than TCI) No AD → rapid-cycling, recent hypomanic, recent functional impairing and rapid mood fluctuations Stop AD → after 8 weeks of symptoms relief (parox, venlafax → higher risk of discontinuation syndrome) Avoid → Lamo a single treatment for BDI Mania, which treatment ? 3 weeks Mania, which treatment ? Mania, which treatment ? Change in mania rating scores Mania, which treatment ? Risk difference for treatment responders Mania, which treatment ? Risk difference for drop outs Conclusion 1 Use second generation AP (risp, olanz, quet) for the treatment of acute mania (3 weeks) Mood stabilizers are second choice Acute depression, which treatment ? Acute depression, which treatment ? Acute depression, which treatment ? Symptom remission Conclusion 2 Use second generation AP (olanz, quet) for the treatment of acute depression during BD Mood stabilizers are less efficacious No strong evidence for using SSRI Maintenance, which treatment ? the same regimen that successfully treated the acute bipolar mood episode attempt monotherapy. However, many bipolar patients require medication combinations First line: lithium, lamotrigine, risperidone (im) Second line: aripiprazole, valproate, quet, olanz Suicide risk → lithium Maintenance → lithium Lithium 41% vs 61% placebo Conclusion 3 For maintenance use the same drug started during acute phase If not possible use lithium, risperidone im, lamotrigine, valp Start with monotherapy, but multitreatment is more effective neuroimaging lithium neuroimaging 1.9 years base-1st fu 4 years base-2nd fu Valproate and AP Overall, no significant brain volume modification in bipolar patients taking valproate or AP Valproate ant AP mechanism Serotonin-glutamate Type II metabotropic glutamate receptors (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers Serotonin-Dopamine-Scaffolding The scaffolding protein PSD-95 is known to interact with N-methyl-D-aspartate (NMDA), D(2) and 5-HT(2) receptors, regulating their activation state Homer1a, the inducible member of the Homer family of PSD proteins that is implicated in glutamatergic signal transduction, is induced in striatum by antipsychotics with high dopamine receptor affinity and in the cortex by antipsychotics with mixed serotonergic/dopaminergic profile Conclusion 4 The molecular events that drive the efficacy of mood stabilizers are related to GSK-3, IPP and prosurvival genetic expression The dopaminergic-serotoninergic-glutamatergic balance is central to the activity of AP in the prefrontal cortex. Scaffolding proteins are thought to be relevant imaging Conclusion 5 Lymbic structures and the PFC are key relay points for the efficacy of pharmacological treatments in BP Schizophrenia skz Treatment First episode → oral AP, address to specialized unit, write a care plan in collaboration with the patient and send it to the GMP, include a crisis plan Provide information and discuss the benefits and disadvantages Chose the AP with the patient, taking into consideration extrapyramidal side effects and metabolic side effects skz Start with the lower dose of AP Justify and record reasons for dosages outside the range given by guidelines Monitor efficacy, side effects, adherence, physical health Record the rationale for continuing, changing or stopping medication and the effects of such changes Trials for one medication should last 4-6 weeks skz Which drug ? Conclusion 6 Second generation AP are more effective for the treatment of Skz Use Olanzapine and Risperidone when possible The side efffect profile must nevertheless guide the clinical choices imaging Conventional antipsychotic agents led to an increase of basal ganglia volume while ongoing multifocal gray matter loss Modern atypical agents rather tend to turn increased basal ganglia volume back to normal while increasing the volume of thalamus and of gray matter in different key regions II AP → ↑ glutamatergic turnover and inhibit NMDA receptors 17 (8m/9f) acute psychotic recurrentepisode (chronic) patients treated with haloperidol or risperidone 30 medication-naive first-episode patients and 36 matched healthy controls participated Atypical antipsychotic treatment Effect of practice on brain activation in the left dorsolateral prefrontal cortex (DLPFC) 8 skz and 8 controls Treated with risperidone for 6 weeks Conclusion 7 II AP increase the DLPC activity This event correlates with outcome Variations in the NAc may be involved during withdrawal